Clinical Trial: NCT03038672
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-11-16 |
Study Overview
Brief Summary
This phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have come back (recurrent) or do not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as varlilumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Official Title
Conditions
Intervention / Treatment
- Biological: Nivolumab
- Drug: Varlilumab
Other Study ID Numbers
- NCI-2017-00120
- NCI-2017-00120
- MC168D
- 10089
- 10089
- UM1CA186686
- UM1CA186709
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-11-16 |
Study Overview
Brief Summary
This phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have come back (recurrent) or do not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as varlilumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Official Title
Conditions
Intervention / Treatment
- Biological: Nivolumab
- Drug: Varlilumab
Other Study ID Numbers
- NCI-2017-00120
- NCI-2017-00120
- MC168D
- 10089
- 10089
- UM1CA186686
- UM1CA186709